{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:03:56Z","timestamp":1780758236307,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.clbc.2018.02.012","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T19:15:49Z","timestamp":1520018149000},"page":"e773-e780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Triple Negative Apocrine Carcinomas as a Distinct Subtype of Triple Negative Breast Cancer: A Case-control Study"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1861-2895","authenticated-orcid":false,"given":"Icro","family":"Meattini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6676-1169","authenticated-orcid":false,"given":"Donato","family":"Pezzulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"Saieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bernini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Orzalesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Jose","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9880-8387","authenticated-orcid":false,"given":"Isacco","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Francolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8999-5208","authenticated-orcid":false,"given":"Pierluigi","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Greto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0360-3275","authenticated-orcid":false,"given":"Mauro","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-6812","authenticated-orcid":false,"given":"Monica","family":"Mangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Nori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Vezzosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2605-4758","authenticated-orcid":false,"given":"Simonetta","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2018.02.012_bib1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1590\/S1807-59322010001000019","article-title":"Triple-negative breast carcinomas are a heterogeneous entity that differs between young and old patients","volume":"65","author":"Carvalho","year":"2010","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.clbc.2018.02.012_bib2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10549-012-2315-y","article-title":"Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up","volume":"136","author":"Malorni","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2018.02.012_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.17305\/bjbms.2016.1811","article-title":"Apocrine carcinoma of the breast: a brief update on the molecular features and targetable biomarkers","volume":"17","author":"Vranic","year":"2017","journal-title":"Bosn J Basic Med Sci"},{"key":"10.1016\/j.clbc.2018.02.012_bib4","doi-asserted-by":"crossref","first-page":"24579","DOI":"10.18632\/oncotarget.15597","article-title":"Dose invasive apocrine adenocarcinoma has worse prognosis than invasive ductal carcinoma of breast: evidence from SEER database","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clbc.2018.02.012_bib5","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1200\/JCO.2013.49.8899","article-title":"Complete response of metastatic androgen receptor-positive breast cancer to bicalutamide: case report and review of the literature","volume":"34","author":"Arce-Salinas","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2018.02.012_bib6","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdw067","article-title":"A\u00a0phase II trial of abiraterone acetate plus prednisonein patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)","volume":"27","author":"Bonnefoi","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2018.02.012_bib7","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1158\/1078-0432.CCR-12-3327","article-title":"Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer","volume":"19","author":"Gucalp","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2018.02.012_bib8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/modpathol.2010.50","article-title":"EGFR and HER-2\/neu expression in invasive apocrine carcinoma of the breast","volume":"23","author":"Vranic","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clbc.2018.02.012_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clbc.2012.09.002","article-title":"Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome","volume":"13","author":"Montagna","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2018.02.012_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.breast.2004.06.003","article-title":"\u2018Pure\u2019 invasive apocrine carcinoma of the breast: a new clinicopathological entity?","volume":"14","author":"Japaze","year":"2005","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2018.02.012_bib11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/PAS.0000000000000671","article-title":"Pure apocrine carcinomas represent a clinicopathologically distinct androgen receptor-positive subset of triple-negative breast cancers","volume":"40","author":"Mills","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clbc.2018.02.012_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.clbc.2012.11.004","article-title":"Immunohistochemically defined subtypes and outcome of apocrine breast cancer","volume":"13","author":"Dellapasqua","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2018.02.012_bib13","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1634\/theoncologist.2014-0108","article-title":"Rare breast cancer subtypes: histological, molecular, and clinical peculiarities","volume":"19","author":"Dieci","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2018.02.012_bib14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1055\/s-0036-1593854","article-title":"The apocrine profile of triple-negative breast carcinomas in patients aged 45 years or younger: favorable but rare features","volume":"38","author":"Masili-Oku","year":"2016","journal-title":"Rev Bras Ginecol Obstet"},{"key":"10.1016\/j.clbc.2018.02.012_bib15","series-title":"Rosen\u2019s Breast Pathology","author":"Hoda","year":"2014"},{"key":"10.1016\/j.clbc.2018.02.012_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JOP.777003","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"6","author":"Hammond","year":"2010","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clbc.2018.02.012_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clbc.2013.02.005","article-title":"Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen","volume":"13","author":"Meattini","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2018.02.012_bib18","series-title":"TNM Classification of Malignant Tumors","year":"2009"},{"key":"10.1016\/j.clbc.2018.02.012_bib19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2559.2002.14691.x","article-title":"Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up","volume":"41","author":"Elston","year":"2002","journal-title":"Histopathology"},{"key":"10.1016\/j.clbc.2018.02.012_bib20","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1158\/0008-5472.CAN-09-0452","article-title":"Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer","volume":"69","author":"Peters","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2018.02.012_bib21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10549-010-0761-y","article-title":"Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers","volume":"124","author":"Castellano","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2018.02.012_bib22","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1158\/1078-0432.CCR-10-2021","article-title":"Androgen receptor expression and breast cancer survival in postmenopausal women","volume":"17","author":"Hu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2018.02.012_bib23","first-page":"1843","article-title":"Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?","volume":"8","author":"Giannos","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clbc.2018.02.012_bib24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.acthis.2012.09.006","article-title":"Expression of androgen receptors in triple negative breast carcinomas","volume":"115","author":"Mrklic","year":"2013","journal-title":"Acta Histochem"},{"key":"10.1016\/j.clbc.2018.02.012_bib25","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1309\/42F00D0DJD0J5EDT","article-title":"Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations","volume":"120","author":"Agoff","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clbc.2018.02.012_bib26","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1136\/jclinpath-2012-200885","article-title":"Reappraisal of immunohistochemical profiling of special histological types of breast carcinomas: a study of 121 cases of eight different subtypes","volume":"65","author":"Alvarenga","year":"2012","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.clbc.2018.02.012_bib27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12282-009-0113-0","article-title":"Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society","volume":"17","author":"Iwase","year":"2010","journal-title":"Breast Cancer"},{"key":"10.1016\/j.clbc.2018.02.012_bib28","first-page":"1481","article-title":"Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers","volume":"27","author":"Choi","year":"2012","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.clbc.2018.02.012_bib29","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.14694\/EdBook_AM.2015.35.e31","article-title":"Triple-negative breast cancer: molecular subtypes and new targets for therapy","author":"Lehmann","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clbc.2018.02.012_bib30","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-16-3055","article-title":"Paclitaxel with or without everolimus in patients with stage II\/III triple-negative breast cancer (TNBC): responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67","volume":"23","author":"Jovanovi\u0107","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2018.02.012_bib31","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.breast.2015.07.009","article-title":"Clinical implications of molecular heterogeneity in triple negative breast cancer","volume":"24","author":"Lehmann","year":"2015","journal-title":"Breast"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820918300156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820918300156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:16:52Z","timestamp":1761513412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820918300156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1526820918300156"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2018.02.012","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple Negative Apocrine Carcinomas as a Distinct Subtype of Triple Negative Breast Cancer: A Case-control Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2018.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}